197892-34-5Relevant academic research and scientific papers
Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality
Borthwick,Crame,Ertl,Exall,Haley,Hart,Mason,Pennell,Singh,Weingarten,Woolven
, p. 1 - 18 (2002)
The stereospecific synthesis of a series of α-methylpyrrolidine-5,5-trans-lactam inhibitors of human cytomegalovirus (HCMV) protease is described. Examination of the SAR in this series has defined the size and chirality of the α-substituent, optimized the
Pyrrolidine-5,5-trans-lactams 3. Alternative regiochemical outcome of the acyl-iminium coupling reaction
Andrews, David M.,Borthwick, Alan D.,Chaignot, Helene,Jones, Paul S.,Robinson, J. Ed,Shah, Pritom,Slater, Martin J.,Upton, Richard J.
, p. 1722 - 1726 (2003)
Enantio- and regioselective syntheses of the pyrrolidine 5,5-trans-lactams benzyl (3aS,6aR)-6,6-dimethyl-5-oxohexahydropyrrolo[3,2-b]pyrrole-1(2H)-carboxylate and benzyl (3aS,6aR)-6S-ethyl-5-oxohexahydropyrrolo[3,2-b]pyrrole-1(2H)-carboxylate from a common intermediate 2-ethoxy-3S-(2,2,2-trifluoro-acetylamino)-pyrrolidine-1-carboxylic acid benzyl ester are reported. The key step in both syntheses is the acyl iminium ion mediated condensation of the pyrrolidine with a ketene acetal.
Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
-
, (2008/06/13)
There are described according to the invention compounds of formula (I) (relative stereochemistry indicated), wherein R1, R2, R3 and X are as defined in the specification, together with processes for preparing them, compositions containing them and their use as pharmaceuticals. Compounds of formula (I) are indicated inter alia for the treatment of chronic bronchitis.
